Research programme: anti-CD3 monoclonal antibody - Affimed Therapeutics

Drug Profile

Research programme: anti-CD3 monoclonal antibody - Affimed Therapeutics

Alternative Names: AFM 15; anti-CD3 monoclonal antibody - Affimed

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Affimed Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Allotransplant rejection

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allotransplant-rejection in Germany
  • 25 Jul 2005 This programme is available for licensing (http://www.affimed.com)
  • 25 Jun 2005 Preclinical trials in Allotransplant rejection in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top